Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAB8LH)

Drug Name

Tildacerfont Drug Info

Synonyms

Tildacerfont; 1014983-00-6; 4-(4-chloro-5-(2,5-dimethyl-7-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl)thiazol-2-yl)morpholine; SCHEMBL2182127; XVAWSBAQNIXMIO-UHFFFAOYSA-N; AKOS040747540; MS-27364; HY-113603; 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-7-(1-ethyl-propyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine; 4-[4-chloro-5-(2,5-dimethyl-7-pentan-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)-1,3-thiazol-2-yl]morpholine; 7-(1-ethyl-propyl)-3-(4-chloro-2-morpholin-4-yl-thiazol-5-yl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine

Indication

Disease Entry	ICD 11	Status	REF
Congenital adrenal hyperplasia	5A71.01	Phase 2	[1]

Cross-matching ID

PubChem CID: 24898977
TTD Drug ID: DMAB8LH

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Corticotropin-releasing factor receptor 1 (CRHR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Telavancin	DM58VQX	Staphylococcus infection	1B5Y	Approved	[3]
Pexacerfont	DMBJ15R	Anxiety disorder	6B00-6B0Z	Phase 2/3	[4]
SSR125543	DMGJEB8	Anxiety disorder	6B00-6B0Z	Phase 2	[5]
ONO-2333Ms	DMOT0WR	Anxiety disorder	6B00-6B0Z	Phase 2	[6]
GSK561679	DMEVARK	Alcohol dependence	6C40.2	Phase 2	[7]
GSK586529	DM5E9LX	Anxiety disorder	6B00-6B0Z	Phase 1	[7]
GW876008	DMAXRBI	Irritable bowel syndrome	DD91.0	Discontinued in Phase 2	[4]
CP-316,311	DMZ76EM	Major depressive disorder	6A70.3	Discontinued in Phase 2	[4]
CRA1000	DMWMBIV	Anxiety disorder	6B00-6B0Z	Preclinical	[3]
NBI-37582	DM3JY2N	Anxiety disorder	6B00-6B0Z	Terminated	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Corticotropin-releasing factor receptor 1 (CRHR1)	TT7EFHR	CRFR1_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05370521) A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects With Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens. U.S.National Institutes of Health.
2	Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021 Nov 30;186(1):R1-R14.
3	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
4	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
5	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
6	Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86.
7	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
8	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.